Did you know there are currently six active AFTD research grant programs to support FTD research at all stages, from discovery research to clinical trials? One of these programs is a partnership with the Alzheimer’s Drug Discovery Foundation, called “Accelerating Drug Discovery for FTD.” This program supports optimization and testing of novel compounds, biologics, or repurposed drugs with up to $350,000 in research funding. AFTD is heartened to see the diversity of therapeutic approaches and targets. Please see below to explore the newly awarded projects.

	Thomas Kukar, PhD, from Emory University, is developing a granulin biologic to treat progranulin-deficient FTD.
	Chenxi Qiu, PhD, from Beth Israel Deaconess Medical Center, is developing a new therapeutic antibody for FTD targeting a specific form of tau.
	James Shorter, PhD, from the University of Pennsylvania, is developing oligonucleotide therapeutics to reverse FUS proteinopathy.